Xeno-free autologous cultivated limbal epithelial transplantation is effective

Article

Using xeno-free autologous cultivated limbal epithelial transplantation has proven to be effective in restoring corneal epithelial stability and improving vision in patients with ocular surface burns

Using xeno-free autologous cultivated limbal epithelial transplantation has proven to be effective in restoring corneal epithelial stability and improving vision in patients with ocular surface burns, according to a paper published in British Journal of Ophthalmology.

Dr Virender S. Sangwan et al., L V Prasad Eye Institute, Kallam Anji Reddy Campus, India, conducted a retrospective study on 200 patients with unilateral total limbal cell deficiency caused by ocular surface burns. Patients were treated between 2001 and 2010 and underwent a small limbal biopsy from the normal eye.

For 10 to 14 days limbal epithelial cells were expanded ex vivo on the human amniotic membrane. This was completed by using a xeno-free explant culture system. The patient's affected eye received cultured epithelial monolayer and amniotic membrane substrate transplantation. The outcome measures included postoperative corneal surface stability, visual improvement and complications.

Of the 200 eyes studied, 142 presented with a fully epithelised, avascular and clinically stable corneal surface with a mean follow-up of 3±1.6 years. In 121 eyes a two-line improvement in visual acuity was found.

The investigation has demonstrated the success of the limbal epithelial transplantation in restoring corneal epithelial stability in patients with ocular burns.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.